Compare Biogen Inc (BIIB) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Match Group Inc — how do they compare? Biogen Inc trades at $194.23 (market cap $28.34B), while Match Group Inc trades at $39.4 (market cap $8.94B). The key difference: Biogen Inc is far larger — about 3.2× Match Group Inc's market cap, and Match Group Inc pays a 2.09% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MTCH | |
|---|---|---|
Market Cap | $28.34B | $8.94B |
Sector | Health | Media |
52-Week High | $216.63 | $39.32 |
52-Week Low | $122.68 | $28.90 |
Enterprise Value | $30.62B | $11.89B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
MTCH trades at $38.54, down 0.8% on the day, with a bullish technical signal from moving averages and strong analyst support (17 buy ratings, 0 sell). The company shows solid fundamentals with 4% revenue growth in Q1 2026, an 18.83% net income margin, and positive cash flow trends. Recent news highlights Tinder's turnaround progress and upcoming Q2 2026 earnings announcement on August 4, 2026.
The stock presents upside potential with a consensus price target of $41.63 (8% upside), supported by improving profitability and cash flow generation. Key risks include Tinder's user decline offset by price increases, high debt levels ($3.85B), and competitive pressures in the dating app space. The current valuation at 14.71 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
